Evidence map›Paper›PMID 34059775›Full record

ArticleScientific reports2021

Dynamic causal modelling of immune heterogeneity.

Thomas Parr, Anjali Bhat, Peter Zeidman, Aimee Goel, Alexander J Billig, Rosalyn Moran, Karl J Friston

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.1field-weighted citation impact, top 62% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Message Passing and Metabolism.Entropy (Basel, Switzerland) · 2021
    Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Thomas ParrWellcome Centre for Human Neuroimaging, Queen Square Institute of Neurology, London, UK. thomas.parr.12@ucl.ac.uk.
Anjali BhatWellcome Centre for Human Neuroimaging, Queen Square Institute of Neurology, London, UK.
Peter ZeidmanWellcome Centre for Human Neuroimaging, Queen Square Institute of Neurology, London, UK.
Aimee GoelRoyal Stoke University Hospital, Stoke-on-Trent, UK.
Alexander J BilligUCL Ear Institute, University College London, London, UK.
Rosalyn MoranCentre for Neuroimaging Science, Department of Neuroimaging, IoPPN, King's College London, London, UK.
Karl J FristonWellcome Centre for Human Neuroimaging, Queen Square Institute of Neurology, London, UK.
National Hospital for Neurology and Neurosurgery · GBUniversity College London · GBWellcome Centre for Human Neuroimaging · GBRoyal Stoke University Hospital · GB

Funding

Medical Research Council D79/543369/D-OTH/170890Wellcome Trust 088130/Z/09/ZWellcome Trust 203147/Z/16/Z
6 · The paper itself

Abstract

An interesting inference drawn by some COVID-19 epidemiological models is that there exists a proportion of the population who are not susceptible to infection-even at the start of the current pandemic. This paper introduces a model of the immune response to a virus. This is based upon the same sort of mean-field dynamics as used in epidemiology. However, in place of the location, clinical status, and other attributes of people in an epidemiological model, we consider the state of a virus, B and T-lymphocytes, and the antibodies they generate. Our aim is to formalise some key hypotheses as to the mechanism of resistance. We present a series of simple simulations illustrating changes to the dynamics of the immune response under these hypotheses. These include attenuated viral cell entry, pre-existing cross-reactive humoral (antibody-mediated) immunity, and enhanced T-cell dependent immunity. Finally, we illustrate the potential application of this sort of model by illustrating variational inversion (using simulated data) of this model to illustrate its use in testing hypotheses. In principle, this furnishes a fast and efficient immunological assay-based on sequential serology-that provides a (1) quantitative measure of latent immunological responses and (2) a Bayes optimal classification of the different kinds of immunological response (c.f., glucose tolerance tests used to test for insulin resistance). This may be especially useful in assessing SARS-CoV-2 vaccines.

Indexed as

Antibodies, ViralAntibody FormationBayes TheoremB-LymphocytesComputer SimulationCOVID-19Cross ReactionsHumansModels, ImmunologicalSARS-CoV-2T-LymphocytesViral LoadAntibodies, Viral

Identifiers

PMID34059775
PMCPMC8167139
OpenAlexW3085809474

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.